EyeGene Inc (185490) — Capital Reinvestment Ratio

Latest as of September 2023: 8.77x

EyeGene Inc (185490) has a Capital Reinvestment Ratio of 8.77x as of September 2023, meaning it reinvests 9% of its operating cash flow (₩541.79 Million) in capital expenditures (₩4.75 Billion). See EyeGene Inc balance sheet quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

8.77x

Capex / Operating Cash Flow

Operating Cash Flow

₩541.79 Million

KRW

Capital Expenditures

₩4.75 Billion

KRW

Data as of

Sep 2023

Most recent filing

Annual Capital Reinvestment Ratio for EyeGene Inc (None–None)

Year-by-year Capital Reinvestment Ratio for EyeGene Inc from None to None. For live market cap and broader valuation context, see EyeGene Inc stock valuation.

Year	Reinvestment Ratio	Operating CF (KRW)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow